BioNTech(BNTX.US)Q1净利润同比增长228%至36.99亿欧元重申全年业绩指引

智通财经2022-05-09

智通财经APP获悉，5月9日(周一)美股盘前，BioNTech(BNTX.US)公布了2022年第一季度财务业绩。财报显示，BioNTech一季度营收为63.75亿欧元，上年同期为20.48亿欧元，同比增长211%;净利润为36.99亿欧元，上年同期为11.28亿欧元，同比增长228%;摊薄后每股收益为14.24欧元，上年同期为4.39欧元。新冠疫苗方面，2022年一季度，该公司与辉瑞已经交付了...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2234782523?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2022-05-09 19:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2234782523","market":"hk","top_or_hot":-1,"title":"BioNTech(BNTX.US)Q1净利润同比增长228%至36.99亿欧元 重申全年业绩指引","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，5月9日(周一)美股盘前，BioNTech(BNTX.US)公布了2022年第一季度财务业绩。财报显示，BioNTech一季度营收为63.75亿欧元，上年同期为20.48亿欧元，同比增长211%;净利润为36.99亿欧元，上年同期为11.28亿欧元，同比增长228%;摊薄后每股收益为14.24欧元，上年同期为4.39欧元。新冠疫苗方面，2022年一季度，该公司与辉瑞已经交付了...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/720516.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BioNTech(BNTX.US)Q1净利润同比增长228%至36.99亿欧元 重申全年业绩指引</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBioNTech(BNTX.US)Q1净利润同比增长228%至36.99亿欧元 重申全年业绩指引\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-05-09 19:12 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/720516.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，5月9日(周一)美股盘前，BioNTech(BNTX.US)公布了2022年第一季度财务业绩。财报显示，BioNTech一季度营收为63.75亿欧元，上年同期为20.48亿欧元，同比增长211%;净利润为36.99亿欧元，上年同期为11.28亿欧元，同比增长228%;摊薄后每股收益为14.24欧元，上年同期为4.39欧元。新冠疫苗方面，2022年一季度，该公司与辉瑞已经交付了...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/720516.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BNTX","symbol_name":"BioNTech SE","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/720516.html","article_id":"2234782523","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2234782523","pubTimestamp":1652094737,"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，5月9日(周一)美股盘前，BioNTech公布了2022年第一季度财务业绩。财报显示，BioNTech一季度营收为63.75亿欧元，上年同期为20.48亿欧元，同比增长211%;净利润为36.99亿欧元，上年同期为11.28亿欧元，同比增长228%;摊薄后每股收益为14.24欧元，上年同期为4.39欧元。截至发稿，BioNTech周一美股盘前跌0.51%，报135.48美元。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":["earning"],"viewcount":null,"language":"zh","relate_stocks":{"BNTX":"BioNTech SE"},"translate_title":"BioNTech (BNTX.US) Q1 net profit increased by 228% year-on-year to 3.699 billion euros, reiterating the annual performance guidelines","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BNTX":1},"content_text":"智通财经APP获悉，5月9日(周一)美股盘前，BioNTech(BNTX.US)公布了2022年第一季度财务业绩。财报显示，BioNTech一季度营收为63.75亿欧元，上年同期为20.48亿欧元，同比增长211%;净利润为36.99亿欧元，上年同期为11.28亿欧元，同比增长228%;摊薄后每股收益为14.24欧元，上年同期为4.39欧元。新冠疫苗方面，2022年一季度，该公司与辉瑞已经交付了7.5亿剂BNT162b2疫苗;截至2022年4月底，两家公司已签署的将于2022年交付的新冠疫苗订单为24亿剂;两家公司正按计划在2022年底前向低收入和中等收入国家提供超过20亿剂新冠疫苗。此外，财报透露，BioNTech与辉瑞正在评估后续的新冠疫苗，包括一款针对Omicron变异株的候选疫苗和针对Omicron变异株和其他SARS-CoV-2毒株的二价疫苗。据悉，BioNTech已授权一项美国存托股票(ADS)的回购计划，根据该计划，该公司可在未来两年来回购最高达15亿美元的ADS;第一批股票回购计划于2022年5月2日开始，价值高达10亿美元。展望未来，BioNTech重申其2022财年展望，即预计2022财年全年新冠疫苗营收在130-170亿欧元的预期;研发费用预计在14-15亿欧元，销售和管理费用在4.5-5.5亿欧元，资本支出在4.5-5.5亿欧元。截至发稿，BioNTech周一美股盘前跌0.51%，报135.48美元。","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"claudebot","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2234782523"}

BioNTech(BNTX.US)Q1净利润同比增长228%至36.99亿欧元 重申全年业绩指引

精彩评论

BioNTech(BNTX.US)Q1净利润同比增长228%至36.99亿欧元重申全年业绩指引